Mike Thompson, MD, PhD, FASCO
@mtmdphd.bsky.social
Views my own. VP Clinical Partnerships @TempusAI
#PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://coi.asco.org/share/RBB-TT6R/Michael
#PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://coi.asco.org/share/RBB-TT6R/Michael
Pinned
Myeloma / Plasma Cell Dyscrasia ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - @mtmdphd
- Update: 6/3/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani
- Update: 6/3/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani
Reposted by Mike Thompson, MD, PhD, FASCO
NOW PUBLISHED!! JPCRR Vol. 12, Issue 4: aah.org/jpcrr. No paywalls. Completely #OpenAccess. Sincerest congratulations to @mtmdphd.bsky.social @bzmorgenstern.bsky.social @annzgeorge.bsky.social
October 1, 2025 at 1:37 PM
NOW PUBLISHED!! JPCRR Vol. 12, Issue 4: aah.org/jpcrr. No paywalls. Completely #OpenAccess. Sincerest congratulations to @mtmdphd.bsky.social @bzmorgenstern.bsky.social @annzgeorge.bsky.social
Real-World Myeloma Pts Remain Under-Represented in #ClinicalTrials Based on Standard Labs & Baseline Characteristics: Analysis of over 3,000 Pts from @TakedaOncology Insight - @dra_v_hungria et al. @AjaiChari - Abs 1887 #ASH19 ashpublications.org/blood/articl... #mmsm
September 11, 2025 at 12:44 PM
Real-World Myeloma Pts Remain Under-Represented in #ClinicalTrials Based on Standard Labs & Baseline Characteristics: Analysis of over 3,000 Pts from @TakedaOncology Insight - @dra_v_hungria et al. @AjaiChari - Abs 1887 #ASH19 ashpublications.org/blood/articl... #mmsm
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
August 20, 2025 at 7:51 PM
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
July 28, 2025 at 9:07 PM
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
July 21, 2025 at 3:15 PM
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
Reposted by Mike Thompson, MD, PhD, FASCO
NOW PUBLISHED!! JPCRR Vol. 12, Issue 3: aah.org/jpcrr. No paywalls. Completely #OpenAccess. Sincerest congratulations to @mtmdphd.bsky.social @bzmorgenstern.bsky.social @annzgeorge.bsky.social
July 16, 2025 at 7:10 PM
NOW PUBLISHED!! JPCRR Vol. 12, Issue 3: aah.org/jpcrr. No paywalls. Completely #OpenAccess. Sincerest congratulations to @mtmdphd.bsky.social @bzmorgenstern.bsky.social @annzgeorge.bsky.social
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
July 14, 2025 at 1:35 AM
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd
Evaluation and comparison of two commercially available targeted next-generation sequencing [NGS] platforms to assist oncology decision making [Apr 24, 2015] @drglenweiss.bsky.social et al. OncoTargets and Therapy ow.ly/KtCZ30pBOTq #PrecisionMedicine
Evaluation and comparison of two commercially available targeted next- | OTT
Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making Glen J Weiss,1 Brandi R Hoff,1 Robert P Whitehead,1 Ashish Sang...
ow.ly
June 13, 2025 at 1:39 PM
Evaluation and comparison of two commercially available targeted next-generation sequencing [NGS] platforms to assist oncology decision making [Apr 24, 2015] @drglenweiss.bsky.social et al. OncoTargets and Therapy ow.ly/KtCZ30pBOTq #PrecisionMedicine
Quantifying the Value of Molecular Tumor Board: Discordance Recommendation Rate & Drug Cost Avoidance [10/20/22] Walters et al. JCO PO @ascocancer.bsky.social ascopubs.org/doi/abs/10.1... #PrecisionMedicine #hpeonc
June 13, 2025 at 1:37 PM
Quantifying the Value of Molecular Tumor Board: Discordance Recommendation Rate & Drug Cost Avoidance [10/20/22] Walters et al. JCO PO @ascocancer.bsky.social ascopubs.org/doi/abs/10.1... #PrecisionMedicine #hpeonc
DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer [Feb 14, 2025] @KamyaSankar et al. @ReckampK Lung Cancer www.lungcancerjournal.info/article/S016... #lcsm #ImmunoOnc #PrecisionMedicine
DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer
DDR genes play a key role in detecting and repairing DNA damage and are crucial for
maintaining the integrity of the genome [1]. Alterations in DDR genes are associated
with genomic instability and in...
www.lungcancerjournal.info
June 4, 2025 at 1:35 PM
DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer [Feb 14, 2025] @KamyaSankar et al. @ReckampK Lung Cancer www.lungcancerjournal.info/article/S016... #lcsm #ImmunoOnc #PrecisionMedicine
Myeloma / Plasma Cell Dyscrasia ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - @mtmdphd
- Update: 6/3/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani
- Update: 6/3/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani
June 4, 2025 at 1:51 AM
Myeloma / Plasma Cell Dyscrasia ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - @mtmdphd
- Update: 6/3/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani
- Update: 6/3/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani
Myeloma / Plasma Cell Dyscrasia *DRAFT* ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - @mtmdphd
- Update: 5/31/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani @CyclingDoctor @MyelomaTeacher
- Update: 5/31/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani @CyclingDoctor @MyelomaTeacher
May 31, 2025 at 11:37 AM
Myeloma / Plasma Cell Dyscrasia *DRAFT* ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - @mtmdphd
- Update: 5/31/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani @CyclingDoctor @MyelomaTeacher
- Update: 5/31/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani @CyclingDoctor @MyelomaTeacher
Myeloma / Plasma Cell Dyscrasia *DRAFT* ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - X: @mtmdphd
- Update: 5/29/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani
- Update: 5/29/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani
May 29, 2025 at 11:08 PM
Myeloma / Plasma Cell Dyscrasia *DRAFT* ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - X: @mtmdphd
- Update: 5/29/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani
- Update: 5/29/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani
Heterogeneity in the expression [RNA] of GPRC5D between patients with multiple myeloma - @Phhersh et al. #ASCO25 Abst 7511 meetings.asco.org/abstracts-pr... #mmsm #PrecisionMedicine #cagenome #caxtx n=290 CD138 purified
May 23, 2025 at 3:51 PM
Heterogeneity in the expression [RNA] of GPRC5D between patients with multiple myeloma - @Phhersh et al. #ASCO25 Abst 7511 meetings.asco.org/abstracts-pr... #mmsm #PrecisionMedicine #cagenome #caxtx n=290 CD138 purified
.@HealthtreeMM Hub: A Patient-Derived, Patient-Driven Clinical Cancer Information Platform Used to Overcome Hurdles & Accelerate Research in Multiple Myeloma [3/10/22] @NSweeneyPhd @AhlstromJenny @FaithEDavies1 @mtmdphd @JCOCCI_ASCO ow.ly/iyIe50Igxhe @myelomacrowd #mmsm
ASCO Publications
ow.ly
May 23, 2025 at 3:44 PM
.@HealthtreeMM Hub: A Patient-Derived, Patient-Driven Clinical Cancer Information Platform Used to Overcome Hurdles & Accelerate Research in Multiple Myeloma [3/10/22] @NSweeneyPhd @AhlstromJenny @FaithEDavies1 @mtmdphd @JCOCCI_ASCO ow.ly/iyIe50Igxhe @myelomacrowd #mmsm
The HealthTree Cure Hub registry: A patient-centered, multicenter approach to advancing multiple myeloma care - Jorge Arturo Hurtado Martínez et al. @HealthTree #ASCO25 Abst e19569 meetings.asco.org/abstracts-pr... #mmsm
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
May 23, 2025 at 3:30 PM
The HealthTree Cure Hub registry: A patient-centered, multicenter approach to advancing multiple myeloma care - Jorge Arturo Hurtado Martínez et al. @HealthTree #ASCO25 Abst e19569 meetings.asco.org/abstracts-pr... #mmsm
Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201 - Landau et al. #ASCO25 #Abst 7508
meetings.asco.org/abstracts-pr... #NCT06097832 #amyloidosis
meetings.asco.org/abstracts-pr... #NCT06097832 #amyloidosis
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
May 23, 2025 at 3:20 PM
Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201 - Landau et al. #ASCO25 #Abst 7508
meetings.asco.org/abstracts-pr... #NCT06097832 #amyloidosis
meetings.asco.org/abstracts-pr... #NCT06097832 #amyloidosis
First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results - van de Donk et al. #ASCO25 Abst 7505
meetings.asco.org/abstracts-pr... #mmsm #caxtx
meetings.asco.org/abstracts-pr... #mmsm #caxtx
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
May 23, 2025 at 3:14 PM
First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results - van de Donk et al. #ASCO25 Abst 7505
meetings.asco.org/abstracts-pr... #mmsm #caxtx
meetings.asco.org/abstracts-pr... #mmsm #caxtx
Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1 - Quach et al. #ASCO25 Abst 7504
meetings.asco.org/abstracts-pr... #mmsm
meetings.asco.org/abstracts-pr... #mmsm
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
May 23, 2025 at 3:05 PM
Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1 - Quach et al. #ASCO25 Abst 7504
meetings.asco.org/abstracts-pr... #mmsm
meetings.asco.org/abstracts-pr... #mmsm
Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results - Lichtman et al. #ASCO25 Abst 7514
meetings.asco.org/abstracts-pr... #NCT05862012 #mmsm #caxtx
meetings.asco.org/abstracts-pr... #NCT05862012 #mmsm #caxtx
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
May 23, 2025 at 2:39 PM
Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results - Lichtman et al. #ASCO25 Abst 7514
meetings.asco.org/abstracts-pr... #NCT05862012 #mmsm #caxtx
meetings.asco.org/abstracts-pr... #NCT05862012 #mmsm #caxtx
GEMINI-NSCLC study: Integrated longitudinal multi-omic biomarker profiling study of non-small cell lung cancer (NSCLC) patients - Palmer et al. #ASCO25 Abst TPS8114 meetings.asco.org/abstracts-pr... @TempusAI @AstraZeneca #LiquidBiopsy #ImmunoOnc #oncorad
May 23, 2025 at 2:13 PM
GEMINI-NSCLC study: Integrated longitudinal multi-omic biomarker profiling study of non-small cell lung cancer (NSCLC) patients - Palmer et al. #ASCO25 Abst TPS8114 meetings.asco.org/abstracts-pr... @TempusAI @AstraZeneca #LiquidBiopsy #ImmunoOnc #oncorad
Outcomes for patients with SPOP-mutated castration-resistant prostate cancer (CRPC) treated with an androgen receptor pathway inhibitor (ARPI) - Park et al. #ASCO25 Abst e17085 meetings.asco.org/abstracts-pr... @TempusAI #pcsm
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
May 23, 2025 at 2:06 PM
Outcomes for patients with SPOP-mutated castration-resistant prostate cancer (CRPC) treated with an androgen receptor pathway inhibitor (ARPI) - Park et al. #ASCO25 Abst e17085 meetings.asco.org/abstracts-pr... @TempusAI #pcsm
Reposted by Mike Thompson, MD, PhD, FASCO
🔥 Just dropped: 6,000+ reasons to get excited for #ASCO25!
From game-changing trials to breakthrough science, the full abstract list is now live @ascocancer.bsky.social
🗓️ Start planning your can’t-miss sessions: meetings.asco.org/abstracts-pr...
From game-changing trials to breakthrough science, the full abstract list is now live @ascocancer.bsky.social
🗓️ Start planning your can’t-miss sessions: meetings.asco.org/abstracts-pr...
May 23, 2025 at 10:04 AM
🔥 Just dropped: 6,000+ reasons to get excited for #ASCO25!
From game-changing trials to breakthrough science, the full abstract list is now live @ascocancer.bsky.social
🗓️ Start planning your can’t-miss sessions: meetings.asco.org/abstracts-pr...
From game-changing trials to breakthrough science, the full abstract list is now live @ascocancer.bsky.social
🗓️ Start planning your can’t-miss sessions: meetings.asco.org/abstracts-pr...
Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment - @VStudiale et al. @AoupPisana @TempusAI #ASCO25 Abst 3544
meetings.asco.org/abstracts-pr... #crcsm #MRD #LiquidBiopsy #PrecisionMedicine
meetings.asco.org/abstracts-pr... #crcsm #MRD #LiquidBiopsy #PrecisionMedicine
May 23, 2025 at 1:55 PM
Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment - @VStudiale et al. @AoupPisana @TempusAI #ASCO25 Abst 3544
meetings.asco.org/abstracts-pr... #crcsm #MRD #LiquidBiopsy #PrecisionMedicine
meetings.asco.org/abstracts-pr... #crcsm #MRD #LiquidBiopsy #PrecisionMedicine
Transcriptomic biomarkers of therapeutic response to antibody-drug conjugates in metastatic breast cancer: A comprehensive multi-center study - @AlkassisSamer et al. #ASCO25 Abst 1041
meetings.asco.org/abstracts-pr... @TempusAI #bcsm #caxtx
meetings.asco.org/abstracts-pr... @TempusAI #bcsm #caxtx
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
May 23, 2025 at 1:13 PM
Transcriptomic biomarkers of therapeutic response to antibody-drug conjugates in metastatic breast cancer: A comprehensive multi-center study - @AlkassisSamer et al. #ASCO25 Abst 1041
meetings.asco.org/abstracts-pr... @TempusAI #bcsm #caxtx
meetings.asco.org/abstracts-pr... @TempusAI #bcsm #caxtx